Hypoxia, HIF1 and glucose metabolism in the solid tumour

Nature Reviews Cancer

Volumn 8, Issue 9, 2008, Pages 705-713

  Denko, Nicholas C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICHLOROACETIC ACID; ECHINOMYCIN; HIF 1 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; INHIBITOR PROTEIN; PDK 1 INHIBITOR; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CELL METABOLISM; DRUG MECHANISM; DRUG TARGETING; GENE CONTROL; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HYPOXIA; MITOCHONDRIAL RESPIRATION; NONHUMAN; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SOLID TUMOR; TUMOR GROWTH;

CELL DIVISION; CELL HYPOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MITOCHONDRIA; MODELS, BIOLOGICAL; NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 50149097983     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2468     Document Type: Review

References (122)

1. Warburg, O. On respiratory impairment in cancer cells. Science 124, 269-270 (1956).
2. Milosevic, M., Fyles, A., Hedley, D. & Hill, R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin. Radiat. Oncol. 14, 249-258 (2004).
3. Brown, J. M. & Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416 (1998).
4. Dasu, A., Toma-Dasu, I. & Karlsson, M. Theoretical simulation of tumour oxygenation and results from acute and chronic hypoxia. Phys. Med. Biol. 48, 2829-2842 (2003).
5. Denko, N. C. et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22, 5907-5914 (2003).
6. Hockel, M. & Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst. 93, 266-276 (2001).
7. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 12, 149-162 (1998).
8. Bardos, J. I. & Ashcroft, M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 26, 262-269 (2004).
9. Gottlieb, E. & Tomlinson, I. P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nature Rev. Cancer 5, 857-866 (2005).
10. Brahimi-Horn, M. C., Chiche, J. & Pouyssegur, J. Hypoxia signalling controls metabolic demand. Curr. Opin. Cell Biol. 19, 223-229 (2007).
11. Kim, J. W., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell. Metab. 3, 177-185 (2006).
12. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L. & Denko, N. C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell. Metab. 3, 187-197 (2006).
13. Zhang, H. et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11, 407-420 (2007).
14. 2 tension. Am. J. Physiol. 271, C1172-C1180 (1996).
15. Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B. & Simon, M. C. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol. Cell. Biol. 23, 9361-9374 (2003).
16. Hu, C. J., Sataur, A., Wang, L., Chen, H. & Simon, M. C. The N-terminal transactivation domain confers target gene specificity of hypoxia inducible factors HIF-1α and HIF-2α. Mol. Biol. Cell (2007).
17. Gordan, J. D., Thompson, C. B. & Simon, M. C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12, 108-113 (2007).
18. 2 sensing. Science 292, 464-468 (2001).
19. Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001).
20. Epstein, A. C. et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 (2001).
21. 2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
22. Stiehl, D. P. et al. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J. Biol. Chem. 281, 23482-23491 (2006).
23. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999).
24. Stickle, N. H. et al. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol. Cell. Biol. 24, 3251-3261 (2004).
25. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246 (2002).
26. Mazure, N. M., Chen, E. Y., Yeh, P., Laderoute, K. R. & Giaccia, A. J. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 56, 3436-3440 (1996).
27. Sheta, E. A., Trout, H., Gildea, J. J., Harding, M. A. & Theodorescu, D. Cell density mediated pericellular hypoxia leads to induction of HIF-1α via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene 20, 7624-7634 (2001).
28. Jiang, B. H., Agani, F., Passaniti, A. & Semenza, G. L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57, 5328-5335 (1997).
29. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C. & Semenza, G. L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21, 3995-4004 (2001).
30. Zundel, W. et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14, 391-396 (2000).
31. Blancher, C., Moore, J. W., Robertson, N. & Harris, A. L. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res. 61, 7349-7355 (2001).
32. Chan, D. A., Sutphin, P. D., Denko, N. C. & Giaccia, A. J. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1α. J. Biol. Chem. 277, 40112-40117 (2002).
33. Pore, N. et al. Akt1 activation can augment hypoxia-inducible factor-1α expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol. Cancer Res. 4, 471-479 (2006).
34. Lu, H. et al. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J. Biol. Chem. 280, 41928-41939 (2005).
35. MacKenzie, E. D. et al. Cell-permeating α-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol. Cell. Biol. 27, 3282-3289 (2007).
36. 2 sensing. J. Biol. Chem. 275, 25130-25138 (2000).
37. Chandel, N. S. et al. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl Acad. Sci. USA 95, 11715-11720 (1998).
38. Brunelle, J. K. et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell. Metab. 1, 409-414 (2005).
39. Guzy, R. D. et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell. Metab. 1, 401-408 (2005).
40. Mansfield, K. D. et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-α activation. Cell. Metab. 1, 393-399 (2005).
41. Gerald, D. et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118, 781-794 (2004).
42. Vaux, E. C., Metzen, E., Yeates, K. M. & Ratcliffe, P. J. Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood 98, 296-302 (2001).
43. Srinivas, V. et al. Oxygen sensing and HIF-1 activation does not require an active mitochondrial respiratory chain electron-transfer pathway. J. Biol. Chem. 276, 21995-21998 (2001).
44. Chi, J. T. et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 3, e47 (2006).
45. Allen, J. W., Khetani, S. R., Johnson, R. S. & Bhatia, S. N. In vitro liver tissue model established from transgenic mice: role of HIF-1alpha on hypoxic gene expression. Tissue Eng. 12, 3135-3147 (2006).
46. Vengellur, A., Woods, B. G., Ryan, H. E., Johnson, R. S. & LaPres, J. J. Gene expression profiling of the hypoxia signaling pathway in hypoxia-inducible factor 1α null mouse embryonic fibroblasts. Gene Expr. 11, 181-197 (2003).
47. Lum, J. J. et al. The transcription factor HIF-1α plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 21, 1037-1049 (2007).
48. Maxwell, P. H. et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA 94, 8104-8109 (1997).
49. Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F. & Maity, A. Regulation of glut1 mRNA by hypoxiainducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 276, 9519-9525 (2001).
50. Airley, R. E. & Mobasheri, A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 53, 233-256 (2007).
51. Brown, G. K. Glucose transporters: structure, function and consequences of deficiency. J. Inherit. Metab. Dis. 23, 237-246 (2000).
52. Ozbudak, I. H., Karaveli, S., Simsek, T., Erdogan, G. & Pestereli, E. Neoangiogenesis and expression of hypoxia-inducible factor 1α, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Gynecol. Oncol. 108, 603-608 (2008).
53. Mathupala, S. P., Rempel, A. & Pedersen, P. L. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J. Biol. Chem. 276, 43407-43412 (2001).
54. Seagroves, T. N. et al. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol. Cell. Biol. 21, 3436-3444 (2001).
55. Minchenko, A. et al. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J. Biol. Chem. 277, 6183-6187 (2002).
56. Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120 (2006).
57. Fantin, V. R., St-Pierre, J. & Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425-434 (2006).
58. Firth, J. D., Ebert, B. L. & Ratcliffe, P. J. Hypoxic regulation of lactate dehydrogenase, A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J. Biol. Chem. 270, 21021-21027 (1995).
59. Ullah, M. S., Davies, A. J. & Halestrap, A. P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism. J. Biol. Chem. 281, 9030-9037 (2006).
60. Baggetto, L. G. Deviant energetic metabolism of glycolytic cancer cells. Biochimie 74, 959-974 (1992).
61. Patel, M. S. & Korotchkina, L. G. Regulation of mammalian pyruvate dehydrogenase complex by phosphorylation: complexity of multiple phosphorylation sites and kinases. Exp. Mol. Med. 33, 191-197 (2001).
62. Roche, T. E. et al. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog. Nucleic Acid Res. Mol. Biol. 70, 33-75 (2001).
63. Corn, P. G. et al. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol. Ther. 4, 1285-1294 (2005).
64. Li, F. et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol. 25, 6225-6234 (2005).
65. Kim, J. W., Gao, P., Liu, Y. C., Semenza, G. L. & Dang, C. V. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 27, 7381-7393 (2007).
66. Fukuda, R. et al. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129, 111-122 (2007).
67. Allen, L. A., Zhao, X. J., Caughey, W. & Poyton, R. O. Isoforms of yeast cytochrome c oxidase subunit V affect the binuclear reaction center and alter the kinetics of interaction with the isoforms of yeast cytochrome c. J. Biol. Chem. 270, 110-118 (1995).
68. David, P. S. & Poyton, R. O. Effects of a transition from normoxia to anoxia on yeast cytochrome c oxidase and the mitochondrial respiratory chain: implications for hypoxic gene induction. Biochim. Biophys. Acta 1709, 169-180 (2005).
69. Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nature Rev. Cancer 4, 891-899 (2004).
70. Droge, W. Free radicals in the physiological control of cell function. Physiol. Rev. 82, 47-95 (2002).
71. Collins, P., Jones, C., Choudhury, S., Damelin, L. & Hodgson, H. Increased expression of uncoupling protein 2 in HepG2 cells attenuates oxidative damage and apoptosis. Liver Int. 25, 880-887 (2005).
72. Muschel, R. J., Bernhard, E. J., Garza, L., McKenna, W. G. & Koch, C. J. Induction of apoptosis at different oxygen tensions: evidence that oxygen radicals do not mediate apoptotic signaling. Cancer Res. 55, 995-998 (1995).
73. Yoshida, T., Maulik, N., Engelman, R. M., Ho, Y. S. & Das, D. K. Targeted disruption of the mouse Sod I gene makes the hearts vulnerable to ischemic reperfusion injury. Circ. Res. 86, 264-269 (2000).
74. Siraki, A. G., Pourahmad, J., Chan, T. S., Khan, S. & O'Brien, P. J. Endogenous and endobiotic induced reactive oxygen species formation by isolated hepatocytes. Free Radic. Biol. Med. 32, 2-10 (2002).
75. Li, C., Wright, M. M. & Jackson, R. M. Reactive species mediated injury of human lung epithelial cells after hypoxia-reoxygenation. Exp. Lung Res. 28, 373-389 (2002).
76. Tuttle, S. W. et al. Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration: implications for the mechanism of HIF-1α stabilization under moderate hypoxia. J. Biol. Chem. 282, 36790-36796 (2007).
77. Chandel, N. S. & Schumacker, P. T. Cellular oxygen sensing by mitochondria: old questions, new insight. J. Appl. Physiol. 88, 1880-1889 (2000).
78. Papandreou, I. et al. Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res. 65, 3171-3178 (2005).
79. Brunelle, J. K. et al. c-Myc sensitization to oxygen deprivation-induced cell death is dependent on Bax/Bak, but is independent of p53 and hypoxia-inducible factor-1. J. Biol. Chem. 279, 4305-4312 (2004).
80. Deberardinis, R. J., Sayed, N., Ditsworth, D. & Thompson, C. B. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18, 54-61 (2008).
81. Buzzai, M. et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24, 4165-4173 (2005).
82. Ramanathan, A., Wang, C. & Schreiber, S. L. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc. Natl Acad. Sci. USA 102, 5992-5997 (2005).
83. Hatzivassiliou, G. et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311-321 (2005).
84. DeBerardinis, R. J. et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA 104, 19345-19350 (2007).
85. Wilson, D. F. & Erecinska, M. The oxygen dependence of cellular energy metabolism. Adv. Exp. Med. Biol. 194, 229-239 (1986).
86. Chandel, N., Budinger, G. R., Kemp, R. A. & Schumacker, P. T. Inhibition of cytochrome-c oxidase activity during prolonged hypoxia. Am. J. Physiol. 268, L918-L925 (1995).
87. Thomlinson, R. H. & Gray, L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9, 539-549 (1955).
88. Secomb, T. W., Hsu, R., Ong, E. T., Gross, J. F. & Dewhirst, M. W. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol. 34, 313-316 (1995).
89. Evans, S. M., Hahn, S. M., Magarelli, D. P. & Koch, C. J. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am. J. Clin. Oncol. 24, 467-472 (2001).
90. Shen, J. et al. Oxygen consumption rates and oxygen concentration in molt-4 cells and their mtDNA depleted (rho0) mutants. Biophys. J. 84, 1291-1298 (2003).
91. Hagen, T., Taylor, C. T., Lam, F. & Moncada, S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1α. Science 302, 1975-1978 (2003).
92. 2-dependent reaction cycle of Ero1-mediated oxidative protein folding in the endoplasmic reticulum. Mol. Cell 10, 983-994 (2002).
93. Forneris, F., Binda, C., Vanoni, M. A., Mattevi, A. & Battaglioli, E. Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process. FEBS Lett. 579, 2203-2207 (2005).
94. Herst, P. M. & Berridge, M. V. Cell surface oxygen consumption: a major contributor to cellular oxygen consumption in glycolytic cancer cell lines. Biochim. Biophys. Acta 1767, 170-177 (2007).
95. Rosenfeld, E., Beauvoit, B., Rigoulet, M. & Salmon, J. M. Non-respiratory oxygen consumption pathways in anaerobically-grown Saccharomyces cerevisiae: evidence and partial characterization. Yeast 19, 1299-1321 (2002).
96. Akakura, N. et al. Constitutive expression of hypoxia-inducible factor-1α renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 61, 6548-6554 (2001).
97. Chen, J. et al. Dominant-negative hypoxia-inducible factor-1α reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am. J. Pathol. 162, 1283-1291 (2003).
98. Kim, W. et al. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol. Cancer Ther. 6, 2554-2562 (2007).
99. Di Cosimo, S. et al. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc.) 39, 157-174 (2003).
100. Tannock, I. F., Guttman, P. & Rauth, A. M. Failure of 2-deoxy-D-glucose and 5-thio-D-glucose to kill hypoxic cells of two murine tumors. Cancer Res. 43, 980-983 (1983).
101. Maher, J. C., Savaraj, N., Priebe, W., Liu, H. & Lampidis, T. J. Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas 30, e34-39 (2005).
102. Liu, H., Savaraj, N., Priebe, W. & Lampidis, T. J. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem. Pharmacol. 64, 1745-1751 (2002).
103. Singh, D. et al. Optimizing cancer radiotherapy with 2-deoxy-D-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther. Onkol. 181, 507-514 (2005).
104. Maschek, G. et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 64, 31-34 (2004).
105. Jha, B. & Pohlit, W. Reversibility of inhibition of DNA double strand break repair by 2-deoxy-D-glucose in Ehrlich ascites tumour cells. Int. J. Radiat. Biol. 63, 459-467 (1993).
106. Varshney, R., Dwarakanath, B. & Jain, V. Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells. Int. J. Radiat. Biol. 81, 397-408 (2005).
107. Fulda, S. & Debatin, K. M. HIF-1-regulated glucose metabolism: a key to apoptosis resistance? Cell Cycle 6, 790-792 (2007).
108. Tanaka, T., Kurose, A., Halicka, H. D., Traganos, F. & Darzynkiewicz, Z. 2-deoxy-D-glucose reduces the level of constitutive activation of ATM and phosphorylation of histone H2AX. Cell Cycle 5, 878-82 (2006).
109. Kurtoglu, M. et al. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol. Cancer Ther. 6, 3049-3058 (2007).
110. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721-732 (2003).
111. Giaccia, A., Siim, B. G. & Johnson, R. S. HIF-1 as a target for drug development. Nature Rev. Drug Discov. 2, 803-811 (2003).
112. Melillo, G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev. 26, 341-352 (2007).
113. Cairns, R. A., Papandreou, I., Sutphin, P. D. & Denko, N. C. Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc. Natl Acad. Sci. USA 104, 9445-9450 (2007).
114. 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J. Nucl. Med. 48, 973-80 (2007).
115. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J. Clin. Oncol. 24, 2098-104 (2006).
116. Matoba, S. et al. p53 regulates mitochondrial respiration. Science 312, 1650-1653 (2006).
117. McFate, T. et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J. Biol. Chem. 9 Jun 2008 (doi:10.1074/jbc.M801765200).
118. + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11, 37-51 (2007).
119. Gleadle, J. M. & Ratcliffe, P. J. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 89, 503-509 (1997).
120. Semenza, G. L., Roth, P. H., Fang, H. M. & Wang, G. L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269, 23757-23763 (1994).
121. Maltepe, E., Schmidt, J. V., Baunoch, D., Bradfield, C. A. & Simon, M. C. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386, 403-407 (1997).
122. Minchenko, O., Opentanova, I. & Caro, J. Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS Lett. 554, 264-270 (2003).